2021 Year in Review: Cholangiocarcinoma

Phase 2 Study Results of Infigratinib in Patients with Previously Treated Advanced CCA Harboring an FGFR2 Gene Fusion or Rearrangement

Cholangiocarcinoma

2021 Year in Review: Cholangiocarcinoma — December 17, 2021

Mature results from a phase 2 study demonstrated that the FGFR inhibitor infigratinib has antitumor activity and a manageable adverse event profile in previously treated patients with locally advanced or metastatic CCA harboring FGFR2 gene fusions or rearrangements.

Real-World Evidence of Natural History of Advanced CCA with FGFR2 Gene Fusion/Rearrangement or Wild-Type FGFR2

Cholangiocarcinoma

2021 Year in Review: Cholangiocarcinoma — December 17, 2021

Real-world evidence demonstrates a survival advantage for patients with CCA harboring FGFR2 fusions/rearrangements compared with those with FGFR2 wild-type CCA.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

CCA News Print Edition

CCA News Weekly e‑Newsletter

2021 Year in Review: Cholangiocarcinoma

Page 4 of 4

Subscribe Today!

I'd like to receive:

Stay In The Know